AGL 5.50 Decreased By ▼ -0.10 (-1.79%)
ANL 8.69 Decreased By ▼ -0.21 (-2.36%)
AVN 75.84 Decreased By ▼ -1.14 (-1.48%)
BOP 5.18 Decreased By ▼ -0.07 (-1.33%)
CNERGY 4.51 Decreased By ▼ -0.14 (-3.01%)
EFERT 81.09 Decreased By ▼ -0.13 (-0.16%)
EPCL 50.00 Decreased By ▼ -0.03 (-0.06%)
FCCL 12.53 Decreased By ▼ -0.63 (-4.79%)
FFL 5.52 Decreased By ▼ -0.18 (-3.16%)
FLYNG 6.95 Decreased By ▼ -0.15 (-2.11%)
FNEL 4.65 Decreased By ▼ -0.11 (-2.31%)
GGGL 8.58 Decreased By ▼ -0.22 (-2.5%)
GGL 14.25 Decreased By ▼ -0.35 (-2.4%)
HUMNL 5.59 Decreased By ▼ -0.08 (-1.41%)
KEL 2.54 Decreased By ▼ -0.09 (-3.42%)
LOTCHEM 27.98 Decreased By ▼ -0.67 (-2.34%)
MLCF 23.70 Decreased By ▼ -0.99 (-4.01%)
OGDC 71.64 Decreased By ▼ -0.87 (-1.2%)
PAEL 15.09 Decreased By ▼ -0.28 (-1.82%)
PIBTL 4.89 Decreased By ▼ -0.09 (-1.81%)
PRL 15.81 Decreased By ▼ -0.39 (-2.41%)
SILK 1.07 No Change ▼ 0.00 (0%)
TELE 8.94 Decreased By ▼ -0.26 (-2.83%)
TPL 7.03 Decreased By ▼ -0.22 (-3.03%)
TPLP 18.31 Decreased By ▼ -0.39 (-2.09%)
TREET 21.03 Decreased By ▼ -0.67 (-3.09%)
TRG 134.55 Decreased By ▼ -2.00 (-1.46%)
UNITY 16.63 Decreased By ▼ -0.39 (-2.29%)
WAVES 9.32 Decreased By ▼ -0.57 (-5.76%)
WTL 1.36 Decreased By ▼ -0.05 (-3.55%)
BR100 4,154 Decreased By -71 (-1.68%)
BR30 15,289 Decreased By -229.2 (-1.48%)
KSE100 41,613 Decreased By -537.4 (-1.28%)
KSE30 15,360 Decreased By -228.1 (-1.46%)
World

EU regulator says AZ clot risk 'very rare' as nations battle virus surges

  • But EMA chief Emer Cooke said no particular risk factor had been identified and the clots may be linked to an immune response to the vaccine.
Published April 8, 2021
Follow us

THE HAGUE: The EU's medicines regulator said Wednesday that blood clots should be listed as a rare side effect of the AstraZeneca jab but the benefits continue to outweigh risks, as several countries battle fresh virus surges amid vaccine shortfalls.

A number of nations have suspended the use of AstraZeneca's vaccine for younger populations after it was earlier banned outright in several places over blood clot scares.

The United Kingdom on Wednesday said it will adopt new medical advice to offer most people under 30 an alternative to AstraZeneca if possible, after reporting 19 deaths from clots among people who received the shot.

The debate comes as countries from Germany to Ukraine and India face new waves of the virus that has now killed more than 2.8 million people.

Governments are scrambling to secure much-needed vaccine doses, with Australia the latest nation to complain of shortages that it blamed on EU export controls.

The European Medicines Agency (EMA) said Wednesday that blood clots should be listed as a "very rare" side effect, encouraging countries to continue its use.

The announcement came after the EMA examined 86 blood clotting cases, 18 of which were fatal, out of around 25 million people in Europe who received the AstraZeneca vaccine. Most of the cases were in women aged under 60.

But EMA chief Emer Cooke said no particular risk factor had been identified and the clots may be linked to an immune response to the vaccine.

"The benefits of the AstraZeneca vaccine in preventing Covid-19 overall outweigh the risk of side effects," she told a news conference.

"It is saving lives."

Comments

Comments are closed.

EU regulator says AZ clot risk 'very rare' as nations battle virus surges

ECC approves wheat import of 450,000MT from Russia

Time to 'say no' to cartels, says PM, as energy bill touches $27bn

Intra-day update: rupee registers improvement against US dollar

UAE, Ukraine to start talks on bilateral trade deal

Oil prices rise after OPEC+ keeps output steady, Russian price cap imposed

Taliban acting defence minister holds talks with UAE president

Cotton arrival falls 40% year-on-year

Engro Corp to pursue potential investment opportunity in tower infrastructure sector

Big tax defaulters: FBR to auction off properties, trademarks

FBR set to fix minimum value for sugar supply